San Diego genetic sequencing pioneer Illumina has been ordered by European Union antitrust regulators to sell cancer test maker Grail, a former spinoff, for completing the acquisition before securing official approval.
San Diego genetic sequencing pioneer Illumina has been ordered by European Union antitrust regulators to sell cancer test maker Grail, a former spinoff, for completing the acquisition before securing official approval.
